✦ LIBER ✦

Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function

✍ Scribed by Daniel D. Gretler; Roberto Guerciolini; Paul J. Williams

Book ID: 117321598
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 127 KB
Volume: 26
Category: Article
ISSN: 0149-2918
DOI: 10.1016/s0149-2918(04)90034-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Insulin Degludec has Similar Pharmacokin

Insulin Degludec has Similar Pharmacokinetic Properties in Subjects with Renal Impairment and Subjects with Normal Renal Function

✍ Kiss, István; Arold, Gerhard; Bøttcher, Susanne G.; Roepstorff, Carsten; Kapor, 📂 Article 📅 2012 🏛 Canadian Diabetes Association 🌐 English ⚖ 51 KB

Pharmacokinetics of naproxen in subjects

Pharmacokinetics of naproxen in subjects with normal and impaired renal function

✍ M. Anttila; M. Haataja; A. Kasanen 📂 Article 📅 1980 🏛 Springer 🌐 English ⚖ 473 KB

Pharmacokinetics and safety of tamsulosi

Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function

✍ Yasushi Miyazawa; Robert A. Blum; Jerome J. Schentag; Hidetaka Kamimura; Hiroshi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 892 KB

Pharmacokinetics of cephacetrile in pati

Pharmacokinetics of cephacetrile in patients with normal or impaired renal function

✍ A. Domínguez-Gil; M. C. Castiñeiras; J. M. Tabernero; J. L. Rodríguez Colmmes; S 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 425 KB

Pharmacokinetics of cefoxitin in patient

Pharmacokinetics of cefoxitin in patients with normal or impaired renal function

✍ M. J. Garcia; A. Dominguez-Gil; J. M. Tabernero; J. A. Sanchez Tomero 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 596 KB

Steady-state pharmacokinetics of nefazod

Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function

✍ R. H. Barbhaiya; M. E. Brady; U. A. Shukla; D. S. Greene 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 604 KB

The steady-state pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were compared in subjects with normal and impaired renal function. Patients: The Study was of parallel group design which included 7 subjects with normal (NOR) ren